RU2018133298A - Способы применения агонистов fxr - Google Patents
Способы применения агонистов fxr Download PDFInfo
- Publication number
- RU2018133298A RU2018133298A RU2018133298A RU2018133298A RU2018133298A RU 2018133298 A RU2018133298 A RU 2018133298A RU 2018133298 A RU2018133298 A RU 2018133298A RU 2018133298 A RU2018133298 A RU 2018133298A RU 2018133298 A RU2018133298 A RU 2018133298A
- Authority
- RU
- Russia
- Prior art keywords
- liver
- dose
- alcoholic
- pharmaceutical composition
- use according
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 10
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 6
- 201000001883 cholelithiasis Diseases 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 208000019423 liver disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 102100038495 Bile acid receptor Human genes 0.000 claims 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 210000003445 biliary tract Anatomy 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000001130 gallstones Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (12)
1. Применение соединения формулы (1)
его стереоизомера, энантиомера, их фармацевтически приемлемой соли или аминокислотного конъюгата при изготовлении лекарственного препарата для лечения или профилактики состояния, опосредованного фарнезоидным Х-рецептором (FXR), например, заболеваний печени или расстройств, где указанное соединение следует вводить при дозе в интервале примерно от 3 мкг до примерно 120 мкг.
2. Применение по п.1, где данное заболевание представляет собой хроническое заболевание печени, например, неалкогольную жировую болезнь печени (NAFLD), неалкогольный стеатогепатит (NASH), лекарственно-индуцированные повреждения желчных протоков, камни в желчном пузыре, цирроз печени, алкогольный цирроз печени, кистозный фиброз, непроходимость желчевыводящих путей, желчекаменную болезнь, фиброз печени.
3. Применение по п.1 или 2, где доза представляет собой суточную дозу.
4. Применение по п.1 или 2, где доза представляет собой двойную суточную дозу.
5. Применение по п.1 или 2, где дозу следует вводить каждые два дня.
6. Применение по любому из предшествующих пунктов, где соединением агониста FXR является соединение A в свободной форме или форме его аминокислотного конъюгата.
7. Фармацевтическая композиция в единичной дозированной форме, содержащая примерно 10 мкг, примерно 30 мкг, примерно 60 мкг, примерно 90 мкг или примерно 120 мкг соединения A, подходящей для перорального введения до максимальной общей дозы примерно 120 мкг в день.
8. Фармацевтическая композиция в единичной дозированной форме по п.7, выбранной из жидкости, таблетки, капсулы.
9. Фармацевтическая композиция в единичной дозированной форме по п.7 или 8 для применения при лечении хронического заболевания печени, например, неалкогольной жировой болезни печени (NAFLD), неалкогольного стеатогепатита (NASH), лекарственно-индуцированных повреждений желчных протоков, камней в желчном пузыре, цирроза печени, алкогольного цирроза печени, кистозного фиброза, непроходимости желчевыводящих путей, желчекаменной болезни, фиброза печени.
10. Фармацевтическая композиция в единичной дозированной форме по п.9 для применения при лечении неалкогольного стеатогепатита (NASH).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298121P | 2016-02-22 | 2016-02-22 | |
| US62/298,121 | 2016-02-22 | ||
| US201662420661P | 2016-12-12 | 2016-12-12 | |
| US62/420,661 | 2016-12-12 | ||
| PCT/IB2017/050963 WO2017145041A1 (en) | 2016-02-22 | 2017-02-20 | Methods for using fxr agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018133298A true RU2018133298A (ru) | 2020-03-24 |
| RU2018133298A3 RU2018133298A3 (ru) | 2020-05-27 |
| RU2743075C2 RU2743075C2 (ru) | 2021-02-15 |
Family
ID=58231666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018133298A RU2743075C2 (ru) | 2016-02-22 | 2017-02-20 | Способы применения агонистов fxr |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11344540B2 (ru) |
| EP (2) | EP3848031A1 (ru) |
| JP (1) | JP6986022B2 (ru) |
| KR (1) | KR20180115270A (ru) |
| CN (2) | CN113679718A (ru) |
| AU (1) | AU2017223155B2 (ru) |
| BR (1) | BR112018016310A2 (ru) |
| CA (1) | CA3013186A1 (ru) |
| CL (1) | CL2018002359A1 (ru) |
| CY (1) | CY1124300T1 (ru) |
| DK (1) | DK3419625T3 (ru) |
| ES (1) | ES2878575T3 (ru) |
| HR (1) | HRP20211032T1 (ru) |
| HU (1) | HUE054819T2 (ru) |
| IL (1) | IL260784B (ru) |
| LT (1) | LT3419625T (ru) |
| MX (1) | MX384205B (ru) |
| PH (1) | PH12018501656A1 (ru) |
| PL (1) | PL3419625T3 (ru) |
| PT (1) | PT3419625T (ru) |
| RU (1) | RU2743075C2 (ru) |
| SI (1) | SI3419625T1 (ru) |
| TW (1) | TWI735546B (ru) |
| WO (1) | WO2017145041A1 (ru) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016242861B2 (en) | 2015-03-31 | 2020-08-20 | Enanta Phamraceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| JP6941109B2 (ja) | 2016-02-22 | 2021-09-29 | ノバルティス アーゲー | Ｆｘｒアゴニストを使用するための方法 |
| US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| GB201616670D0 (en) * | 2016-09-30 | 2016-11-16 | Innospec Ltd | Methods, compositions and uses relating thereto |
| MX2019003790A (es) | 2016-10-04 | 2019-09-26 | Enanta Pharm Inc | Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos. |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| AR114930A1 (es) | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
| MX2020004405A (es) | 2017-11-01 | 2020-08-06 | Bristol Myers Squibb Co | Compuestos biciclicos en puente como moduladores del receptor farnesoide x. |
| WO2019089672A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Spirocyclic compounds as farnesoid x receptor modulators |
| WO2019089670A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| US11286252B2 (en) | 2017-11-01 | 2022-03-29 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| CN111278817B (zh) | 2017-11-01 | 2023-05-16 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的多环化合物 |
| EP3716977A1 (en) * | 2017-11-30 | 2020-10-07 | Novartis AG | Fxr agonists for the treatment of liver diseases |
| WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| EA202192244A1 (ru) | 2019-02-15 | 2022-01-24 | Бристол-Маерс Сквибб Компани | Замещенные амидные соединения, применимые в качестве модуляторов фарнезоидного x-рецептора |
| KR20210130757A (ko) | 2019-02-15 | 2021-11-01 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 치환된 비시클릭 화합물 |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| JP7550777B2 (ja) | 2019-02-15 | 2024-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物 |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2020240483A1 (en) * | 2019-05-29 | 2020-12-03 | Qing Bile Therapeutics Inc. | Combination of a polyhydroxylated bile acid and a farnesoid x receptor agonist |
| CA3139291A1 (en) | 2019-07-18 | 2021-01-21 | Jacky Vonderscher | Method for decreasing adverse-effects of interferon |
| WO2021044351A1 (en) * | 2019-09-06 | 2021-03-11 | Novartis Ag | Methods of treating liver disease using lta4h inhibitors |
| US20220331341A1 (en) * | 2019-09-30 | 2022-10-20 | Novartis Ag | Treatment comprising the use of fxr agonists |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists for treating an infection by hepatitis d virus |
| US20240100125A1 (en) | 2021-01-14 | 2024-03-28 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| WO2022229302A1 (en) | 2021-04-28 | 2022-11-03 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| ES2670984T3 (es) | 2013-11-05 | 2018-06-04 | Novartis Ag | Composiciones y métodos para modular receptores X farnesoides |
| AR099558A1 (es) | 2014-02-20 | 2016-08-03 | Merck Patent Gmbh | Régimen de dosaje del compuesto fgf-18 |
| JP6941109B2 (ja) | 2016-02-22 | 2021-09-29 | ノバルティス アーゲー | Ｆｘｒアゴニストを使用するための方法 |
| CA3014731A1 (en) * | 2016-02-22 | 2017-08-31 | Novartis Ag | Methods for using fxr agonists |
-
2017
- 2017-02-20 AU AU2017223155A patent/AU2017223155B2/en not_active Ceased
- 2017-02-20 JP JP2018544236A patent/JP6986022B2/ja not_active Expired - Fee Related
- 2017-02-20 HU HUE17709189A patent/HUE054819T2/hu unknown
- 2017-02-20 RU RU2018133298A patent/RU2743075C2/ru active
- 2017-02-20 KR KR1020187023682A patent/KR20180115270A/ko not_active Ceased
- 2017-02-20 ES ES17709189T patent/ES2878575T3/es active Active
- 2017-02-20 PL PL17709189T patent/PL3419625T3/pl unknown
- 2017-02-20 LT LTEP17709189.9T patent/LT3419625T/lt unknown
- 2017-02-20 WO PCT/IB2017/050963 patent/WO2017145041A1/en not_active Ceased
- 2017-02-20 EP EP21152135.6A patent/EP3848031A1/en not_active Withdrawn
- 2017-02-20 SI SI201730836T patent/SI3419625T1/sl unknown
- 2017-02-20 CN CN202111030869.7A patent/CN113679718A/zh active Pending
- 2017-02-20 BR BR112018016310-4A patent/BR112018016310A2/pt not_active Application Discontinuation
- 2017-02-20 CA CA3013186A patent/CA3013186A1/en active Pending
- 2017-02-20 EP EP17709189.9A patent/EP3419625B1/en active Active
- 2017-02-20 MX MX2018010100A patent/MX384205B/es unknown
- 2017-02-20 HR HRP20211032TT patent/HRP20211032T1/hr unknown
- 2017-02-20 CN CN201780010381.3A patent/CN108697702A/zh active Pending
- 2017-02-20 US US16/078,409 patent/US11344540B2/en active Active
- 2017-02-20 DK DK17709189.9T patent/DK3419625T3/da active
- 2017-02-20 PT PT177091899T patent/PT3419625T/pt unknown
- 2017-02-22 TW TW106105850A patent/TWI735546B/zh not_active IP Right Cessation
-
2018
- 2018-07-25 IL IL260784A patent/IL260784B/en unknown
- 2018-08-03 PH PH12018501656A patent/PH12018501656A1/en unknown
- 2018-08-17 CL CL2018002359A patent/CL2018002359A1/es unknown
-
2021
- 2021-07-05 CY CY20211100600T patent/CY1124300T1/el unknown
-
2022
- 2022-04-26 US US17/660,673 patent/US20220313677A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| RU2018133158A (ru) | Способы применения агонистов fxr | |
| CN101959429B (zh) | 抗微生物肽系统的激动剂 | |
| ES2772754T3 (es) | Pemafibrato para uso en el tratamiento de la enfermedad del hígado graso no alcohólico | |
| JP2018021046A5 (ru) | ||
| JP2018507914A5 (ru) | ||
| CN105120872B (zh) | 包含15-hepe的组合物以及其使用方法 | |
| RU2017130849A (ru) | Дейтерированная производная хенодезоксихолевой кислоты и фармацевтическая композиция, содержащая данное соединение | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| BR112012015282A2 (pt) | composição farmacêutica de liberação controlada | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| RU2018133157A (ru) | Способы применения агонистов fxr | |
| JP2015510916A5 (ru) | ||
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP6878596B2 (ja) | Ｆｘｒアゴニストの組合せ | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| JP2019218379A5 (ru) | ||
| RU2017127509A (ru) | Композиции и способы для улучшенного мышечного метаболизма | |
| JP2016505050A5 (ru) | ||
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| US11628163B2 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
| RU2020121222A (ru) | Агонисты fxr для лечения заболеваний печени | |
| RU2017126153A (ru) | Фармацевтическая комбинация |